Single domain antibodies (sdAbs) are small antibody fragments derived from heavy chain-only antibodies found in camelids, such as llamas and alpacas. At Protheragen-ING, we are committed to providing high-quality sdAb-based drug delivery systems (DDS) tailored to your specific needs.

Advantages of sdAbs

sdAbs offer numerous advantages over traditional intact antibodies, making it an attractive option for DDS.

• Small size: sdAbs are relatively small, with a molecular weight of about 15 kDa, facilitating tissue permeation and glomerular filtration.
• Simple structure: sdAbs consist of a single polypeptide chain and do not contain the connecting regions of light and heavy chains, making it relatively simple in structure.
• High stability: Due to their simple structure, sdAbs usually have high thermal stability and enzyme resistance.
• High affinity and specificity: sdAbs have high affinity and specificity by targeting the antigen-binding sites of specific antigens.

Fig. 1 Schematic diagram of the domain of a camelid heavy chain antibody. (Wesolowski J, et al. 2009)

Our sdAbs Development Services

Protheragen-ING specializes in the development of cutting-edge DDSs based on sdAbs. our team of experienced scientists and researchers offers a comprehensive range of services to support your drug development efforts. Below is a list of our main services:

• Target Identification and Validation

We assist in identifying and validating the right target for your therapeutic needs, ensuring optimal efficacy and safety.

• sdAbs Screening and Identification

By using high-throughput screening techniques and bioinformatics analysis, we can screen candidate molecules with high affinity and specificity from multiple sdAbs libraries and perform comprehensive identification and validation.

• sdAbs Engineering Optimization

Based on customer needs, we can optimize sdAbs through genetic engineering techniques, including affinity improvement, stability enhancement, and drug carrier ligation, to achieve better drug delivery performance.

• Conjugation and Payload Delivery

We affix sdAbs to therapeutic payloads, such as cytotoxic agents, radionuclides, or visualization agents, to create targeted drug delivery systems tailored to your specific requirements.

• sdAbs DDS Evaluation

We utilize in vitro and in vivo experimental models to perform comprehensive evaluations of sdAbs DDSs, including studies of drug release kinetics, targeting efficacy, biodistribution, and safety.

Our Extensive Expertise

Screening and selection of different antigens leads to sdAbs against a wide range of diseases and pathological processes, providing solutions for a broad range of therapeutic areas.

We have expertise in developing sdAbs for a wide range of targets. We can develop sdAbs for a variety of therapeutic applications, including, but not limited to:

• Cancer Targeting: sdAbs target specific cancer markers or receptors for the delivery of anti-cancer drugs, radionuclides, or imaging agents.
• Inflammatory Diseases: sdAbs are designed to target inflammatory molecules or receptors to provide localized delivery of anti-inflammatory drugs.
• Infectious Diseases: sdAbs targeting viral or bacterial targets for the development of targeted antiviral or antibacterial therapies.
• Neurological Diseases: sdAbs target disease-specific molecules involved in neurodegenerative diseases to facilitate the delivery of therapeutic agents to the central nervous system.

The above are only examples, we can develop customized types of sdAbs based on our clients' specific needs and project requirements.

Our Antibody Development Workflow

(1) Antigen preparation.

(2) Animal immunization.

(3) Phage library generation.

(4) Phage library screening and sdAb validation.

(5) Recombinant antibody production.

(6) Recombinant antibody quality control.

Please contact us today to talk about how our sdAbs development services can speed up your drug discovery and development process.